DYADIC INTERNATIONAL INC
Close on Oct 19, 2026
- Market cap
- $13.88M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $961.14K | $-0.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $1.11M | $-0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | $-0.06 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | $393.57K | $-0.07 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $1.96M | $-0.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Press releases
Announcements Dyadic International filed with the SEC
International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Announces Continued Listing on The Nasdaq Capital Market
Other events · EX-99.1 to Form 8-K
Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Regulation FD disclosure · EX-99.1 to Form 8-K
and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS
Results of operations · EX-99.1 to Form 8-K
Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Results of operations · EX-99.1 to Form 8-K
Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
International, Inc. Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions
Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
DYADIC REPORTS 2024 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATES
Results of operations · EX-99.1 to Form 8-K
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Results of operations · EX-99.1 to Form 8-K
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
DYADIC REPORTS 2023 FULL YEAR RESULTS AND RECENT COMPANY PROGRESS
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Dyadic Announces Change in Board and Management Leadership Roles
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Dyadic Announces Closing of Private Placement of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Dyadic ’ s C1 Platform Selected by the
Other events · EX-99.1 to Form 8-K
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus TM
Material agreement · Other events · EX-99.1 to Form 8-K
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
Material agreement · Other events · EX-99.1 to Form 8-K
DYADIC REPORTS 2022 YEAR END RESULTS AND RECENT COMPANY PROGRESS
Results of operations · EX-99.1 to Form 8-K
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein
Other events · EX-99.1 to Form 8-K
Dyadic Announces Sale of Equity Interest in Alphazyme
Material agreement · Other events · EX-99.1 to Form 8-K
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
Results of operations · EX-99.1 to Form 8-K